Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms D-LIFT
- 31 Aug 2020 Primary endpoint, change in liver fat, has been met as per results published in the Diabetologia
- 31 Aug 2020 Results published in the Diabetologia
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.